Fresenius SE Return on Investment 2016-2024 | FSNUY
Current and historical return on investment (ROI) values for Fresenius SE (FSNUY) over the last 10 years.
| Fresenius SE ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2024-06-30 |
$0.69B |
$32.92B |
1.91% |
| 2024-03-31 |
$1.00B |
$33.71B |
2.41% |
| 2023-12-31 |
$1.24B |
$33.67B |
2.64% |
| 2023-09-30 |
$2.51B |
$44.82B |
4.82% |
| 2023-06-30 |
$3.02B |
$53.46B |
5.58% |
| 2023-03-31 |
$3.33B |
$55.79B |
6.13% |
| 2022-12-31 |
$3.50B |
$53.95B |
6.49% |
| 2022-09-30 |
$4.09B |
$53.65B |
7.58% |
| 2022-06-30 |
$4.39B |
$53.95B |
8.09% |
| 2022-03-31 |
$4.72B |
$54.01B |
8.68% |
| 2021-12-31 |
$4.92B |
$54.32B |
9.17% |
| 2021-09-30 |
$4.86B |
$54.60B |
9.30% |
| 2021-06-30 |
$4.97B |
$54.62B |
9.66% |
| 2021-03-31 |
$4.98B |
$51.03B |
10.00% |
| 2020-12-31 |
$5.01B |
$48.94B |
10.27% |
| 2020-09-30 |
$5.19B |
$51.46B |
10.70% |
| 2020-06-30 |
$5.14B |
$47.84B |
10.82% |
| 2020-03-31 |
$5.16B |
$46.76B |
10.95% |
| 2019-12-31 |
$5.19B |
$47.81B |
10.99% |
| 2019-09-30 |
$5.18B |
$47.67B |
11.79% |
| 2019-06-30 |
$5.13B |
$46.30B |
12.71% |
| 2019-03-31 |
$6.19B |
$46.93B |
16.49% |
| 2018-12-31 |
$6.20B |
$34.78B |
17.74% |
| 2018-09-30 |
$6.10B |
$33.51B |
16.50% |
| 2018-06-30 |
$6.20B |
$35.04B |
15.64% |
| 2018-03-31 |
$5.16B |
$36.45B |
12.48% |
| 2017-12-31 |
$5.19B |
$42.80B |
12.11% |
| 2017-09-30 |
$5.24B |
$44.26B |
12.67% |
| 2017-06-30 |
$5.12B |
$41.95B |
13.14% |
| 2017-03-31 |
$5.03B |
$42.30B |
13.44% |
| 2016-12-31 |
$4.79B |
$36.81B |
13.52% |
| 2016-09-30 |
$11.39B |
$34.85B |
32.57% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.458B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
